{"url_path":"/sec/artv/8-k/2026-09-11/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-09-11","source_url":"https://www.sec.gov/Archives/edgar/data/1817241/0001193125-26-389308-index.html","accession_number":"0001193125-26-389308","cik":"0001817241","ticker":"ARTV","issuer_name":"Artiva Biotherapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1817241/0001193125-26-389308-index.html","primary_entity_key":"0001817241","primary_entity_name":"Artiva Biotherapeutics, Inc."},"word_count":287,"has_tables":true,"body_markdown":"Item 5.07\n\nSubmission of Matters to a Vote of Security Holders.\n\n \n\n(a) At the Annual Meeting, the Company’s stockholders voted on the proposals listed below, each of which was described in the 2026 Proxy Statement. As of July 20, 2026, the record date for the Annual Meeting, 48,885,777 shares of common stock were outstanding and entitled to vote at the Annual Meeting. The voting results are set forth below.\n\n(b)\n\nProposal 1. Election of Class II Directors\n\nThe Company’s stockholders elected the persons listed below as Class II directors each to serve a three-year term through the Company’s 2029 annual meeting of stockholders and until their successors have been elected and qualified or until earlier resignation or removal. The final voting results are as follows:\n\n \n\nVotes For\n\nVotes Withheld\n\nBroker\nNon-Votes\n\nBrian Daniels, M.D.\n\n33,591,967\n\n5,774,914\n\n4,640,922\n\nLaura Stoppel, Ph.D.\n\n33,862,513\n\n5,504,368\n\n4,640,922\n\n \n\nProposal 2. Ratification of Appointment of Independent Registered Public Accounting Firm\n\nThe Company’s stockholders ratified the appointment of KPMG LLP as the Company’s principal independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results are as follows:\n\nVotes For\n\nVotes Against\n\nAbstentions\n\nBroker\nNon-Votes\n\n44,000,762\n\n4,325\n\n2,716\n\n—\n\n \n\nProposal 3. To Approve an Amendment to the Artiva Biotherapeutics, Inc. 2024 Equity Incentive Plan\n\nThe Company’s stockholders approved an amendment to the 2024 Plan to, among other things, increase the number of shares of common stock authorized for issuance under the plan by 5,097,095 shares and to include in the calculation of the annual automatic share reserve increase shares of common stock issuable upon the exercise of any pre-funded warrants. The final voting results are as follows:\n\nVotes For\n\nVotes Against\n\nAbstentions\n\nBroker\nNon-Votes\n\n32,527,133\n\n6,816,989\n\n22,759\n\n4,640,922"}